Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens. Results of the Phase 2, open-label study indicate the antibody, known as UB-421, was safe and did not induce the production of antibody-resistant HIV.
from All Top News -- ScienceDaily http://bit.ly/2Zo6k8D
Here different kind of articles available for people, simple and easy tips related to different topics.
No comments:
Post a Comment